NCT05987332

Open on CT.gov ↗

Primary endpoint added: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: — PHASE2

NCT05987332 • Phase 2

Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE2

NCT05987332 • Phase 2 • Status: Recruiting → Active, not recruiting